The UK and US have reached a important bilateral deal that will ensure no duties on British drug exports being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the public health system. This move guarantees that tariffs on these vital goods will stay at nothing for a timeframe of the next three years.
This agreement follows recent threats to hike duties on patented pharmaceutical products, with potential rates discussed as high as 100%.
"This deal with the United Kingdom reinforces the international landscape for new treatments and introduces long-overdue fairness to transatlantic pharmaceutical trade," a release said.
Economic Importance
Medicines represent one of the Britain's most significant export categories to the US, which is easily the biggest destination for leading British pharmaceutical firms.
Trade data reveal that in the 12 months prior to September, the UK shipped medicines worth £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that timeframe.
"This agreement secures employment, increases funding and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The deal entails several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. In the past, repayments topped twenty percent.
Industry Background
The pact comes amid a ongoing dispute between the sector and the ministers over spending levels and approval rates.
These tensions were intensified by claims that American consumers were charged several times more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward American operations.
A senior figure publicly accepted that the NHS had to spend more on medicines, noting that its budget allocation on drugs had shrunk as a share of its total funding over the last ten years.
